Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting…
Denmark’s leading life science companies, public foundations, municipalities, universities and hospitals will work together to position Copenhagen as the world…